SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$99.04
−0.23%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$96.43
From 52W high−9.07%
Volume1.47M
Market cap$9.41B
P/E (TTM)—
P/S (TTM)103.9x
Div yield—
Key dataNov 4, 2026
Open
$96.43
From 52W high
−9.07%
Volume
1.47M
Market cap
$9.41B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−30.3x
P/E (TTM)
—
RSI (14)
54.4
MomentumView details →
1D Return
−0.23%
YTD Return
+189.50%
SummaryUpdated Sep 1, 2026
Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a preclinical-stage biotechnology company founded in 2013 and headquartered in Waltham, Massachusetts. The company went public in April 2016 and underwent a significant strategic transformation in November 2023, when it changed its name from Aeglea BioTherapeutics to Spyre Therapeutics to reflect its new focus on inflammatory bowel disease treatments. This pivot marked a complete shift from the company's previous focus on rare genetic diseases to developing novel antibody therapies for patients suffering from inflammatory bowel disease.
Similar companies
Latest newsMore news →
Spyre Therapeutics, Inc. said enrollment in Part B of its Phase 2 SKYLINE trial is ahead of schedule and that it increased enrollment to support topline induction results for three potential combinations expected in Q3 2027.2d agoSpyre Therapeutics, Inc. announced positive topline induction data for SPY003 from Part A of its Phase 2 SKYLINE trial, completing proof-of-concept for its three inflammatory bowel disease monotherapies.2d agoSpyre Therapeutics, Inc. reported its third-quarter 2026 financial results.2d ago